CN101773545B - Leucocyte increasing medicament containing batyl alcohol - Google Patents
Leucocyte increasing medicament containing batyl alcohol Download PDFInfo
- Publication number
- CN101773545B CN101773545B CN2009102444152A CN200910244415A CN101773545B CN 101773545 B CN101773545 B CN 101773545B CN 2009102444152 A CN2009102444152 A CN 2009102444152A CN 200910244415 A CN200910244415 A CN 200910244415A CN 101773545 B CN101773545 B CN 101773545B
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- compositions
- medicine extract
- medicine
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 35
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 title claims abstract description 21
- IWWCATWBROCMCW-UHFFFAOYSA-N batyl alcohol Natural products CCCCCCCCCCCCCCCCCCOC(O)CO IWWCATWBROCMCW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 229960003513 batilol Drugs 0.000 claims description 7
- 206010020718 hyperplasia Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 3
- 235000019634 flavors Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000009636 Huang Qi Substances 0.000 claims description 2
- 230000008030 elimination Effects 0.000 claims description 2
- 238000003379 elimination reaction Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 201000002364 leukopenia Diseases 0.000 description 6
- 231100001022 leukopenia Toxicity 0.000 description 6
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 230000037396 body weight Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 201000010000 Agranulocytosis Diseases 0.000 description 3
- 239000003390 Chinese drug Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000292 leukogenic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- CCHNOBQMQBSRHQ-UHFFFAOYSA-N phosphoric acid;7h-purin-6-amine Chemical compound OP(O)(O)=O.NC1=NC=NC2=C1NC=N2 CCHNOBQMQBSRHQ-UHFFFAOYSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition containing batyl alcohol and traditional Chinese medicine extracts, and the application thereof in preparing medicaments for promoting leucocyte proliferationincrease.
Description
Invention field
This invention relates to the treatment disease in the blood system, the Integrative Chinese-Western medicine of leukopenia and agranulocytosis.
Background technology
Leukopenia and agranulocytosis are internal medicine blood system commonly encountered diseases, frequently-occurring disease, and its pathogenic factor can or infect and other disease causes because of chemical factors such as medicine (as benzolism), and partly cause is not clear.Particularly in the therapeutic process of many tumor diseases, need to use chemotherapy or actinotherapy treatment mostly, these two kinds of therapies all can be killed and wounded human leukocytes in a large number, it is the important pathogenesis of primary disease, many tumour patients often can not continue to accept chemotherapy or radiotherapy because of leukopenia causes, so that lose the therapy apparatus meeting, cause the development and the deterioration of tumor.Therefore, the treatment primary disease is particularly treated the leukopenia problem in tumour patient radiotherapy, the chemotherapy process, becomes the key subjects of domestic and international medical circle.
Though modern medicine has had deep understanding for the cause of disease, but in treatment, still lack new means, Therapeutic Method does not have major progress in recent years, generally adopts group vitamins leukocyte increasing (as adenine phosphate), colony stimulating factor and use adrenocortical hormone to reduce the leukocyte that causes because of immunity to destroy.These therapies, curative effect is unsatisfactory, and with some serious adverse comparatively, has limited the clinical scope of application.
The traditional Chinese medical herbal treatment primary disease, general employing determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs, vigorate qi and replenish the blood, grow methods such as anti-tonifying YANG, though some patient is had curative effect preferably, but it is cumbersome with decocting for Chinese herbal medicine, dose is excessive and the time is long, how can influence disadvantages such as appetite, it is very few that the clinical application that has limited tumour patient serves as based on the leukocyte increasing of Chinese medicine to raise variety in the existing market of Chinese medicine preparation of main effect, and generally be compound preparation, and flavour of a drug are many, curative effect is extensively and not special, and especially the effect of leukocyte increasing is slowly and not remarkable.
The objective of the invention is to, the medicine that provides a kind of Chinese medicine and western medicine to unite use, Chinese medicine and Western medicine can be brought into play synergism, reduce the side effect of Western medicine on the one hand, onset rapidly on the other hand.This medicine can be used for various acute and chronic leukopenias or agranulocytosis, is particularly useful for because of the above-mentioned disease due to tumor disease radiotherapy or the chemotherapy.In leukocyte increasing, there is not the toxic and side effects of other similar Western medicine, it is also few that degradation reacts under the appetite due to other Chinese medicine because of taking.
Summary of the invention
This invention compositions realizes as follows: by weight
95 parts of 1 part of Chinese medicine extract of batilol
Wherein Chinese medicine extract prepares according to the method for putting down in writing in the Chinese patent CN1058908A description: 0.15 part of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi
Earlier Caulis Spatholobi is carried out coarse pulverization, preparing burden in proportion with other three flavors medicine in the back, puts and soak 7-10 hour in the container.Decoct with water respectively then three times, time was respectively 1.5,1,0.5 hours, three fried liquid are merged, slow fire be concentrated into 1: 1 (g: ml) elimination insoluble matter, add 95% ethanol to pure content 80%, left standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
One object of the present invention is to provide the purposes of above-mentioned Pharmaceutical composition in the medicine of preparation promotion leucocyte hyperplasia.
This Chinese medical concrete is called " the described Chinese medicine extract of this paper (or above) " hereinafter.
Above-mentioned composition and mixing acceptable accessories can be made acceptable forms clinically, as tablet, capsule, granule, oral liquid, subcutaneous administration preparation, suppository etc.
Pharmacological research
The main pharmacodynamics of Pharmaceutical composition of the present invention studies confirm that it has the effect that promotes leucocyte hyperplasia more by force, i.e. leukogenic effect.
Cyclophosphamide 120mg/kg/ day is injected in healthy Kunming mouse abdominal cavity continuously, continuous three days, treat that peripheral blood kind leukocyte reduces to 1000/mm
3After, begin to take and respectively organize medicine, set up leukopenia model after the mice chemotherapy, carry out the pharmacodynamics test that Pharmaceutical composition of the present invention promotes leucocyte hyperplasia.Each is organized medicine and used 7 days continuously, irritates stomach every day 1 time, 10 of every group of mices.
The test grouping:
1 model control group: after the animal model modeling success, normal physiological saline is irritated stomach;
2 pure Chinese drug-treated group: extractum 0.95g/kg body weight as indicated above
3 batilol groups: the 10mg/kg body weight is irritated stomach
4 compositions groups: 10mg/kg body weight batilol+extractum 0.95g/kg body weight mentioned above is irritated stomach.
| Group | The leukocyte number |
| Group 1 | 1017±105.1/mm 3 |
| Group 2 | 1941±112.4/mm 3 |
| Group 3 | 2214±184.9/mm 3 |
| Group 4 | 3043±195.9/mm 3 |
This table shows that all there is significant difference (P＜0.05) in each group (pure Chinese drug-treated group, batilol group, compositions group) of treatment with model control group, and all there are significant difference (P＜0.05) in compositions group and pure Chinese drug-treated group, compositions group and batilol group.Show that there are cooperative effect in batilol and described Chinese medicinal components in the compositions group.
The pharmaceutics test
Can produce the tablet that contains following component in a conventional manner:
Wherein compositions is made up of with weight ratio batilol and Chinese medicine extract mentioned above at 1: 95.
Can produce the capsule that contains following component in a conventional manner:
Wherein compositions is made up of with weight ratio batilol and Chinese medicine extract mentioned above at 1: 95.
Claims (2)
1. compositions that promotes leucocyte hyperplasia, it comprises by weight
95 parts of 1 part of Chinese medicine extract of batilol
Wherein Chinese medicine extract prepares according to following method: 0.15 part of elder generation of 0.2 part of Radix Salviae Miltiorrhizae of 0.5 part of Fructus Ligustri Lucidi of 1 part of Radix Astragali of Caulis Spatholobi carries out coarse pulverization with Caulis Spatholobi, prepare burden in proportion with other three flavors medicine in the back, put and soak 7-10 hour in the container, decoct with water respectively then three times, time was respectively 1.5,1,0.5 hours, three fried liquid are merged, slow fire concentrates, the elimination insoluble matter adds 95% ethanol to pure content 80%, leaves standstill 12 hours, filter, the molten partially recycled ethanol of alcohol gets pure clear paste, is required Chinese medicine extract.
2. the purposes of compositions as claimed in claim 1 in the medicine of preparation promotion leucocyte hyperplasia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102444152A CN101773545B (en) | 2009-12-30 | 2009-12-30 | Leucocyte increasing medicament containing batyl alcohol |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102444152A CN101773545B (en) | 2009-12-30 | 2009-12-30 | Leucocyte increasing medicament containing batyl alcohol |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101773545A CN101773545A (en) | 2010-07-14 |
| CN101773545B true CN101773545B (en) | 2011-12-21 |
Family
ID=42510220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102444152A Expired - Fee Related CN101773545B (en) | 2009-12-30 | 2009-12-30 | Leucocyte increasing medicament containing batyl alcohol |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101773545B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103169796A (en) * | 2011-12-20 | 2013-06-26 | 王佳丽 | Medicine for treating agranulocytosis with fungal infection of blood disease patients |
| CN106109425A (en) * | 2016-01-14 | 2016-11-16 | 上海信谊万象药业股份有限公司 | A kind of batilol solid preparation and preparation method thereof |
-
2009
- 2009-12-30 CN CN2009102444152A patent/CN101773545B/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN101773545A (en) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102258563B (en) | Anti-cancer medicinal composition and Chinese medicinal composition | |
| CN102210844B (en) | A traditional Chinese medicine composition for treating chronic hepatitis and its preparation method | |
| CN101091769B (en) | Medicine for treating and preventing esophagus cancer and gastric cancer, and preparation method | |
| CN101062146A (en) | Chinese traditional medicine for treating gastric cancer and bone cancer | |
| CN100425252C (en) | Medicine for treating leukopenia | |
| CN101773545B (en) | Leucocyte increasing medicament containing batyl alcohol | |
| CN101439088B (en) | Medicament for promoting leucocyte hyperplasia | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN103223149B (en) | Chinese herb medicine composition for treating lung cancer | |
| CN101721471B (en) | Leucocyte-raising medicine containing leucogen | |
| CN100441205C (en) | Medicine for treating blood system disease | |
| CN100443092C (en) | Granulocyte raised drug comprising cepharanthine | |
| CN101780142B (en) | Leukogenic medicament containing lithium carbonate | |
| CN101773660B (en) | Medicament containing anubi-polypeotide | |
| CN104435545B (en) | A kind of Chinese medicine preparation for treating caused by benzene leukopenia | |
| CN100381163C (en) | Medicine comprising rilmenidine | |
| CN101439089B (en) | Medicament containing oxymatrine | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN101559196B (en) | Medicament for treating the hyperplasia of mammary glands and preparation method thereof | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN104223062B (en) | Root bark of Chinese wolf-berry health care oral liquid of a kind of reducing pressure and sugar and preparation method thereof | |
| CN102225155A (en) | A kind of pharmaceutical composition for treating pulmonary fibrosis | |
| CN104940554A (en) | Chinese herbal composition for treating heart diseases | |
| CN101732688A (en) | Amlodipine-containing medicament | |
| CN100496543C (en) | Injection for treating cardiac cerebrovascular disease and its preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: NINGBO JIANGBEI WEIMAN BIOTECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZHANG XIXIN Effective date: 20111018 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| C53 | Correction of patent for invention or patent application | ||
| CB03 | Change of inventor or designer information |
Inventor after: Zhang Chunjie Inventor after: Zhang Xixin Inventor before: Zhang Xixin |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHANG XIXIN TO: ZHANG CHUNJIE ZHANG XIXIN Free format text: CORRECT: ADDRESS; FROM: 100020 CHAOYANG, BEIJING TO: 315021 NINGBO, ZHEJIANG PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111018 Address after: Jiangbei District Yongjiang street 315021 Ring Road East of Zhejiang city of Ningbo province No. 134 room C-220 Applicant after: Ningbo Jiangbei Weiman Biological Technology Co., Ltd. Address before: 100020, B320, building 3, Dacheng International, No. 80 East Fourth Ring Road, Beijing, Chaoyang District Applicant before: Zhang Xixin |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| DD01 | Delivery of document by public notice |
Addressee: Zhang Xixin Document name: Notification of Passing Examination on Formalities |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20111221 Termination date: 20121230 |